

RECORDATI APPOINTS MILAN ZDRAVKOVIC AS EXECUTIVE VICE PRESIDENT R&D

Milan, 16th October 2023 - Recordati, a global pharmaceutical company, announces the appointment of Milan Zdravkovic as its Executive Vice President of Research & Development (R&D). The news confirms Recordati's continued commitment to affordable innovation.

Milan Zdravkovic, a Danish national, brings a wealth of experience to his new role, with an impressive track record in developing innovative compounds and leading R&D organizations within the pharmaceutical industry. His expertise spans a wide range of therapeutic areas, including diabetes, obesity, immunology, hematology, and infectious diseases, and with experience from both rare and non-rare diseases. He has 25 years of life-science experience and has worked at pharma and biotech companies like Novo Nordisk, SOBI-Swedish Orphan Biovitrum and SNIPR Biome, holding increasingly senior roles including Head of R&D and Chief Medical Officer.

Recordati CEO Robert Koremans said, "I am delighted to welcome Milan to the company. His broad therapeutic knowledge, rare disease experience, and global leadership will be invaluable as we strengthen our R&D teams. He will play a pivotal role in accelerating our life cycle management program and delivering on our strategic ambitions."

Commenting on his appointment, Milan Zdravkovic stated, "Recordati has an impressive track record in establishing a sustainably growing and profitable business, with a strong understanding of addressing unmet patient needs. I am excited to be able to make a contribution to the company's 100-year legacy, and am humbled and excited to lead R&D. I look forward to working together with my colleagues to contribute to the company's future success."

Raffaele Sabia, who has played a pivotal role in establishing Recordati's current R&D and Medical Affairs functions, has been appointed as Chief Medical Officer, heading up the Global Medical Office including Medical Affairs, Health Economics & Outcome Research, Patient Advocacy and Patient Safety. He will also lead the Recordati Rare Diseases Foundation, contributing to its mission of making a meaningful impact in healthcare and the broader community. "I would like to thank Raffaele for his commitment to building a strong foundation for R&D within Recordati and I look forward to seeing the impact his expertise can have in his new role," said Robert Koremans.

Recordati (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2022, Recordati employed more than 4,300 people and consolidated revenue of € 1,853.3 million.

We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their life. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing.

For more information, please visit www.recordati.com.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office
Via Matteo Civitali, 1
20148 Milano, Italy
Tel. +39 02 487871
Fax +39 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l.

Investor Relations

Federica De Medici

+ 39 02 48787146

investorelations@recordati.itInvestor Relations

Lucia Abbatantuoni

+ 39 02 48787213

investorelations@recordati.itMedia Relations

Brunswick: Barbara Scalchi / Andrea Mormandi

+ 39 02 9288 6200

recordati@brunswickgroup.com

This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast as a result of a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the activities of the Recordati Group, and, as such, it is not intended as a medical scientific indication or recommendation, or as advertising.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1

20148 Milano, Italy

Tel. +39 02 487871

Fax +39 02 40073747

www.recordati.com

Share Capital € 26.140.644,50 fully paid-up

Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Tax Code/VAT No. 00748210150

Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l.